As health professionals administer the Pfizer-BioNTech and Moderna mRNA-based COVID-19 vaccines, other companies are working to develop viral vector-based vaccines to combat coronavirus and other viral diseases. Viral vectors require cells to grow, but certain viral vectors can only be produced on adherent cell cultures, while others can also be produced on suspension cell cultures. Vaccine manufacturers often encounter significant challenges in scaling up the adherent cell cultures used for these treatments, and novel technologies are needed to facilitate safe, rapid production.